• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical ophthalmology >Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion
【24h】

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion

机译：玻璃体内雷珠单抗对视网膜分支静脉浆液性视网膜脱离的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: The aim of this study was to evaluate the effect of initial intravitreal ranibizumab injection on visual acuity (VA) and central macular thickness (CMT) for the treatment of macular edema (ME) with and without serous retinal detachment (SRD) secondary to branch retinal vein occlusion (BRVO). Materials and methods: Fifty-two BRVO eyes, treated with intravitreal ranibizumab injection for ME with and without SRD, were retrospectively reviewed. Patients were divided into two groups according to spectral domain optical coherence tomography (SD-OCT). The efficacy of intravitreal ranibizumab injection at first month was assessed by analyzing the change in best-corrected VA and reduction in CMT with SD-OCT. Results: There were 21 patients with SRD and 31 patients with only CME (no-SRD). CMT was significantly greater in the SRD group than in the CME group (451±62.2 μm vs 383.5±37.2 μm, respectively, P 0.05). After initial intravitreal ranibizumab injection, mean VA improved from 0.87±0.26 logarithm of the minimum angle of resolution (LogMAR) to 0.54±0.27 LogMAR ( P 0.01) and CMT decreased from 451±62.2 μm to 379.3±58.6 μm ( P 0.001) in the SRD group. In the no-SRD group, mean VA improved from 0.69±0.25 LogMAR to 0.44±0.25 LogMAR ( P 0.001) and the CMT decreased from 383.5±37.2 μm to 337.7±39.4 μm ( P 0.001) at the first month visit. Eyes with SRD revealed better anatomic results and greater reduction of CMT after intravitreal ranibizumab injection ( P 0.01). Conclusion: VA and CMT can be improved by intravitreal ranibizumab injection in BRVO patients with and without SRD. However, more marked improvement in macular morphology was achieved in patients with SRD than those without SRD.
机译：目的：本研究的目的是评估玻璃体腔内雷珠单抗初始注射对视力（VA）和中央黄斑厚度（CMT）的影响，以治疗伴或不伴继发于浆液性视网膜脱离（SRD）的继发性黄斑水肿（ME）。视网膜分支静脉阻塞（BRVO）。材料和方法：回顾性分析52枚BRVO眼，分别接受玻璃体腔内雷珠单抗注射治疗伴有和不伴有SRD的ME。根据光谱域光学相干断层扫描（SD-OCT）将患者分为两组。通过分析最佳校正后的VA的变化和SD-OCT降低的CMT来评估玻璃体内雷珠单抗注射液在第一个月的疗效。结果：21例SRD患者和31例仅CME（无SRD）。 SRD组的CMT显着高于CME组（分别为451±62.2μm和383.5±37.2μm，P <0.05）。首次玻璃体腔注射兰尼单抗后，平均VA从最小分辨角（LogMAR）的0.87±0.26对数提高到0.54±0.27 LogMAR（P <0.01），CMT从451±62.2μm降低到379.3±58.6μm（P <0.001 ）在SRD组中。在非SRD组中，第一个月访视的平均VA从0.69±0.25 LogMAR改善至0.44±0.25 LogMAR（P <0.001），CMT从383.5±37.2μm降低至337.7±39.4μm（P <0.001）。玻璃体内注射兰尼单抗后，SRD眼的解剖结果更好，CMT降低更大（P <0.01）。结论：玻璃体腔注射雷珠单抗可改善有无SRD的BRVO患者的VA和CMT。但是，与没有SRD的患者相比，患有SRD的患者在黄斑形态上的改善更大。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号